C4X Discovery Holdings PLC
LSE:C4XD

Watchlist Manager
C4X Discovery Holdings PLC Logo
C4X Discovery Holdings PLC
LSE:C4XD
Watchlist
Price: 12 GBX 27.32% Market Closed
Market Cap: 30.3m GBX
Have any thoughts about
C4X Discovery Holdings PLC?
Write Note

Net Margin
C4X Discovery Holdings PLC

42.8%
Current
-176%
Average
0%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
42.8%
=
Net Income
10.6m
/
Revenue
24.7m

Net Margin Across Competitors

Country UK
Market Cap 30.3m GBP
Net Margin
43%
Country US
Market Cap 1.3T USD
Net Margin
9%
Country US
Market Cap 196.3B USD
Net Margin
14%
Country US
Market Cap 170.3B USD
Net Margin
18%
Country KR
Market Cap 66.5T KRW
Net Margin
24%
Country CH
Market Cap 37.6B CHF
Net Margin
9%
Country US
Market Cap 38.5B USD
Net Margin
22%
Country US
Market Cap 36.7B USD
Net Margin
9%
Country US
Market Cap 26.4B USD
Net Margin
21%
Country US
Market Cap 23B USD
Net Margin
17%
Country US
Market Cap 22.3B USD
Net Margin
-36%
No Stocks Found

C4X Discovery Holdings PLC
Glance View

Market Cap
30.3m GBX
Industry
Life Sciences Tools & Services

C4X Discovery Holdings Plc engages in the development of new technologies to improve the drug discovery process for novel small molecule therapies. The firm operates by early commercial partnering or initiation of a its drug discovery program to develop a small molecule. The firm also works in collaboration with partners. The firm has a portfolio ranging from early stage-target to late-stage drug discovery program ready for out-licensing to partners. The Company’s portfolio of pre-clinical small molecule candidates includes Oral NRF2 activator, Oral MALT1 inhibitor, Oral α4β7 integrin inhibitor, Oral Orexin-1 Antagonist (C4X_3256/INDV-2000), Oral IL-17A Inhibitor. The company has developed activators of the NRF2 pathway for the treatment of a variety of inflammatory diseases including Inflammatory Bowel Disease (IBD), Sickle Cell Disease (SCD), Pulmonary Arterial Hypertension (PAH) and Chronic Obstructive Pulmonary Disorder (COPD).

C4XD Intrinsic Value
43.44 GBX
Undervaluation 72%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
42.8%
=
Net Income
10.6m
/
Revenue
24.7m
What is the Net Margin of C4X Discovery Holdings PLC?

Based on C4X Discovery Holdings PLC's most recent financial statements, the company has Net Margin of 42.8%.